29 May 2025 : Clinical Research
Pentraxin 3 as a Prognostic Biomarker in Aneurysmal Subarachnoid Hemorrhage
Dong-Liang Wang ABCD 1, Feng Jiao BCDE 1, Yi-Lin Jiang ABC 1, Hai-Dong Song ABC 1, Bin Li BCD 2, Qun Gao BD 2, Bin Wang DF 2, Bo Hei CDF 2, Jing-Ru Zhou AF 2*DOI: 10.12659/MSM.947133
Med Sci Monit 2025; 31:e947133
Table 2 Clinical characteristics of patients with different prognoses.
| Clinical parameters | Poor prognosis (n=31) | Good prognosis (n=34) | t/χ2/Z value | P value |
|---|---|---|---|---|
| Age (years) | 54.1±5.8 | 52.3±6.4 | 1.184 | 0.241 |
| Female [n (%)] | 18 (58.1%) | 16 (47.1%) | 0.787 | 0.375 |
| Aneurysm location [anterior circulation, n (%)] | 24 (77.4%) | 22 (64.7%) | 1.267 | 0.260 |
| Aneurysm size (mm) | 7.5±1.7 | 6.9±1.6 | 1.466 | 0.148 |
| MAP (mmHg) | 114 (108–118) | 110 (105–113) | 2.150 | 0.032 |
| Blood glucose (mmol/L) | 8.6 (7.2–12.1) | 7.8 (6.5–9.2) | 1.190 | 0.057 |
| Acute hydrocephalus [n (%)] | 10 (32.3%) | 4 (11.8%) | 4.030 | 0.045 |
| Pneumonia [n (%)] | 18 (58.1%) | 8 (23.5%) | 8.058 | 0.005 |
| PTX3 (ng/ml) | 2.340±0.980 | 1.460±0.564 | 4.486 | <0.001 |
| PTX3 – pentraxin 3; MAP – mean arterial pressure. | ||||